Overview

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2026-02-12

Target enrollment:

Participant gender:

Summary

This phase I trial finds out the best dose and side effects of venetoclax and tocilizumab in treating patients with t(11;14) multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Tocilizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Tocilizumab is used to treat side effects from immune therapy in patients with myeloma. Giving venetoclax and tocilizumab may kill more cancer cells.

Phase:

Phase 1

Details

Lead Sponsor:

Emory University

Collaborator:

National Cancer Institute (NCI)

Treatments:

Immunoglobulin G
Immunoglobulins
Venetoclax